EP1175215A2 - L'osanetant dans le traitement des troubles de l'humeur - Google Patents

L'osanetant dans le traitement des troubles de l'humeur

Info

Publication number
EP1175215A2
EP1175215A2 EP00918941A EP00918941A EP1175215A2 EP 1175215 A2 EP1175215 A2 EP 1175215A2 EP 00918941 A EP00918941 A EP 00918941A EP 00918941 A EP00918941 A EP 00918941A EP 1175215 A2 EP1175215 A2 EP 1175215A2
Authority
EP
European Patent Office
Prior art keywords
osanetant
treatment
disorders
mood disorders
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00918941A
Other languages
German (de)
English (en)
French (fr)
Inventor
Xavier Emonds-Alt
Philippe Soubrie
Regis Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of EP1175215A2 publication Critical patent/EP1175215A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the subject of the present invention is a new use of the osanetant.
  • the osanetant is the International Nonproprietary Name (INN) of (R) - (+) - N - [(3- (1-benzoyl-3- (3,4-dichlorophenyl) piperidin-3-yl) propyl) -4 - phenylpiperidin-4-yl] -N-methyl acetamide of formula:
  • ososetant and its pharmaceutically acceptable salts are useful in the treatment of mood disorders, in particular in the treatment of depression.
  • depression is meant in particular major depressive disorders minor depressive disorders, dysthymic disorders, depressive disorders associated with anxiety as well as depressive disorders associated with bipolar disorders.
  • ososetant The effect of ososetant on major depressive disorders is studied in patients aged 18 to 65 years. Patients receive osmetanant (200 mg / day) for a period of approximately 6 weeks. The improvement in depressive syndromes is measured by a significant decrease in scores on the Hamilton scale (J. Neurol. Neurosurg. Psychiat., 1960, 23, 56-62) as well as by the collection of impressions from the clinician and overall patient impressions.
  • the subject of the present invention is the use of the osanetant and its pharmaceutically acceptable salts for the preparation of drugs useful in the treatment of mood disorders, particularly in the treatment of depression.
  • Ososetant and its pharmaceutically acceptable salts are prepared according to European patent application EP 673 928, likewise the pharmaceutical compositions can be prepared according to the description of this same patent application.
  • compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration
  • the active ingredient alone or in combination with another active ingredient can be administered in unit form of administration, in admixture with conventional pharmaceutical carriers, to animals and humans.
  • Suitable unit administration forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral administration forms, aerosols, implants, forms subcutaneous, transdermal, intramuscular, intravenous, intranasal and rectal administration forms.
  • the daily dosage of the compound according to the invention is from 0.05 to 5 mg / kg, advantageously from 1 to 2.5 mg / kg, preferably from 2 to 2.5 mg / kg, to be administered in one or more times.
  • the compounds are generally formulated in dosage unit containing from 2.5 to 500 mg, advantageously from 50 to 250 mg, preferably from 100 to 250 mg, of active principle per dosage unit, to be administered once, twice or more times , as required.
  • these dosages are examples of average situations, there may be special cases where higher or lower dosages are appropriate, such dosages also belong to the invention.
  • the appropriate dosage for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of said patient.
  • oral forms of administration are preferred.
  • the compounds according to the invention can be administered in combination with another active principle, in particular another antidepressant such as a lithium salt, a tricyclic antidepressant, a monoamine oxidase inhibitor or a serotonin reuptake reuptake inhibitor, by example.
  • another antidepressant such as a lithium salt, a tricyclic antidepressant, a monoamine oxidase inhibitor or a serotonin reuptake reuptake inhibitor, by example.
  • the invention also relates to a method of treatment of mood disorders, more particularly, to a method of treatment of depression, by administration to the patient of an appropriate dose of osanetant or of a pharmaceutically salt thereof. acceptable.
  • EXAMPLE 1 Capsule with 250 mg of osanetant. osanetant 250 mg lactose monohydrate (200 mesh) 40.80 mg corn starch 40.80 mg povidone K-30 8.40 mg purified water * 90.00 mg magnesium stearate 3.40 mg for an opaque white capsule of size 0 , filled to 343.4 mg
  • EXAMPLE 2 Capsule with 100 mg of osanetant. osanetant 100 mg lactose monohydrate (200 mesh) 115.80 mg corn starch 115.80 mg povidone K-30 8.40 mg purified water * 90.00 mg magnesium stearate 3.40 mg for an opaque white capsule of size 0 , filled to 343.4 mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP00918941A 1999-04-13 2000-04-11 L'osanetant dans le traitement des troubles de l'humeur Withdrawn EP1175215A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904699 1999-04-13
FR9904699A FR2792199B3 (fr) 1999-04-13 1999-04-13 Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
PCT/FR2000/000924 WO2000061125A2 (fr) 1999-04-13 2000-04-11 L'osanetant dans le traitement des troubles de l'humeur

Publications (1)

Publication Number Publication Date
EP1175215A2 true EP1175215A2 (fr) 2002-01-30

Family

ID=9544412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00918941A Withdrawn EP1175215A2 (fr) 1999-04-13 2000-04-11 L'osanetant dans le traitement des troubles de l'humeur

Country Status (25)

Country Link
US (1) US6420388B1 (id)
EP (1) EP1175215A2 (id)
JP (1) JP2002541190A (id)
KR (1) KR20010105418A (id)
CN (1) CN1354662A (id)
AR (1) AR023452A1 (id)
AU (1) AU3971600A (id)
BG (1) BG105984A (id)
BR (1) BR0009704A (id)
CA (1) CA2369638A1 (id)
CZ (1) CZ20013645A3 (id)
EE (1) EE200100527A (id)
FR (1) FR2792199B3 (id)
HR (1) HRP20010741A2 (id)
HU (1) HUP0200655A3 (id)
ID (1) ID30458A (id)
IS (1) IS6098A (id)
MX (1) MXPA01010340A (id)
NO (1) NO20014953L (id)
PE (1) PE20010032A1 (id)
PL (1) PL351554A1 (id)
SK (1) SK14552001A3 (id)
TR (1) TR200102930T2 (id)
WO (1) WO2000061125A2 (id)
ZA (1) ZA200108289B (id)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095904A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
CA2549956C (en) * 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
WO2005094801A1 (en) * 2004-03-25 2005-10-13 Smithkline Beecham Corporation Use of an nk3 antagonist for the treatment of bipolar disorders
US8193146B2 (en) * 2005-03-15 2012-06-05 Sumitomo Chemical Company, Limited Method of ameliorating symptom caused by mood disturbance
JP2006320201A (ja) * 2005-05-17 2006-11-30 Sumitomo Chemical Co Ltd 気分障害又は関連障害による疾患症状を改善させる方法
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2015200594A2 (en) * 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2738819B1 (fr) 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
AU4176997A (en) 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0061125A2 *

Also Published As

Publication number Publication date
AU3971600A (en) 2000-11-14
CA2369638A1 (en) 2000-10-19
MXPA01010340A (es) 2002-05-06
CZ20013645A3 (cs) 2002-01-16
HRP20010741A2 (en) 2002-10-31
WO2000061125A2 (fr) 2000-10-19
FR2792199B3 (fr) 2001-05-18
US6420388B1 (en) 2002-07-16
KR20010105418A (ko) 2001-11-28
TR200102930T2 (tr) 2002-04-22
AR023452A1 (es) 2002-09-04
NO20014953D0 (no) 2001-10-11
JP2002541190A (ja) 2002-12-03
IS6098A (is) 2001-09-28
FR2792199A1 (fr) 2000-10-20
EE200100527A (et) 2002-12-16
ZA200108289B (en) 2002-12-24
WO2000061125A3 (fr) 2001-04-19
CN1354662A (zh) 2002-06-19
SK14552001A3 (sk) 2002-02-05
HUP0200655A2 (hu) 2002-07-29
NO20014953L (no) 2001-12-11
BG105984A (bg) 2002-04-30
BR0009704A (pt) 2002-01-08
PL351554A1 (en) 2003-05-05
ID30458A (id) 2001-12-06
PE20010032A1 (es) 2001-04-11
HUP0200655A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
EP1221952B1 (fr) UTILISATION D'UN ANTAGONISTE DES RECEPTEURS AUX CANNABINOiDES CENTRAUX POUR LA PREPARATION DE MEDICAMENTS
US5075338A (en) Method of treatment of learning deficiency
CH672068A5 (id)
EP0369887B1 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
US5220068A (en) Psychostimulant agent
FR2837706A1 (fr) Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
EP1173179A2 (fr) Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles depressifs majeurs
EP1175215A2 (fr) L'osanetant dans le traitement des troubles de l'humeur
EP0429360B1 (fr) Inhibition du syndrome d'abstinence
FR2501506A1 (fr) Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
EP0412901B1 (fr) Utilisation de trifluorométhyl-phényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles de la motricité intestinale
CH679553A5 (id)
CH678149A5 (id)
US6011054A (en) Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin
EP2146714A1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
KR20010110798A (ko) 신경퇴화의 치료방법
WO2000066117A1 (fr) Utilisation du (2s)-1- [(2r,3s)-5- chloro-3- (2-chlorophenyl)-1- (3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h-indole-2-carbonyl] pyrrolidine- 2-carboxamide pour la preparation de medicaments utiles dans le traitement du phenomene de raynaud
JP2610735B2 (ja) 抗鬱剤および抗ストレス剤組成物
FR2639227A1 (fr) Utilisation de derives du chromane pour le traitement des etats depressifs
CA2658614A1 (fr) Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
FR2912058A1 (fr) Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
EP2146713A2 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
FR2711527A1 (fr) Utilisation de l'acriflavine comme agent anti HIV.
FR2527077A1 (fr) Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique
FR2585573A1 (fr) Medicament pour prevenir l'abus d'alcool

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20011113

17Q First examination report despatched

Effective date: 20031024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040308

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041822

Country of ref document: HK